Chargement en cours...
Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
BACKGROUND: Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on edoxaban has not been performed. Our ongoing postmarketing surveillance, ETNA‐AF‐Japan (Edoxaban Treatment in r...
Enregistré dans:
| Publié dans: | J Arrhythm |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6373660/ https://ncbi.nlm.nih.gov/pubmed/30805052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/joa3.12149 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|